99%+ Purity Guarantee

Undergoes independent third-party verification before release. Tested to confirm ≥99% purity.

Buy CJC-1295 Without DAC (5 mg) Online

Name: CJC-1295 Without DAC (5 mg)
Brand: NOVERA COMPOUNDS
Availability: InStock

Coming Soon

CJC-1295 Without DAC is a short-acting growth hormone-releasing hormone analogue with a half-life of 30 minutes to 2 hours. Research suggests that it stimulates pulsatile growth hormone release mimicking natural rhythms, potentially reducing desensitization risk while maintaining physiological GH secretion patterns.

General info

Brand	NOVERA COMPOUNDS
Strength	5mg
CAS	863288-34-0
Chemical Formula	C₁₅₂H₂₅₂N₄₄O₄₂
Molecular weight	33367.954 g/mol
Peptide Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Synonyms	MOD-GRF(1-29), CJC-1295 without DAC, modgrf, tetrasubstituted grf, modified grf
Storage	Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.

Disclaimer: Sold as a research-grade lyophilized peptide in dry powder form. Requires reconstitution under controlled laboratory conditions. Reconstitution agents are not included.

For Research Use Only (RUO): Not for human or animal use, consumption, injection, or application. Not for diagnostic, therapeutic, or clinical purposes.

Buy More Peptides for Research Buy More Muscle Growth & Performance Peptides Products

Free Shipping Over $1000

With fast order dispatch

Guaranteed Product Authenticity

All products contain original LOT numbers

Secure SSL
Encryption

Your data is safe with us

No Order
Minimum

Get the exact quantity you need.

Why Novera Compounds?

Precision-Synthesized Peptides

Advanced synthesis techniques ensure high structural fidelity and ≥99% purity.

Third-Party Verified Quality:

Independent laboratories confirm identity, purity, and batch consistency.

Research-Grade Reliability:

Designed for reproducible laboratory and analytical applications.

Strict Regulatory Compliance:

Products meet Research Use Only (RUO) standards and relevant laboratory regulations.

Documented Transparency:

Certificates of Analysis and quality verification reports provided for every lot.

555a76c773c8ed79615174887299fb4c5c66d2ad

CJC-1295 Without DAC About This Product

CJC-1295 Without DAC, also known as Modified GRF (1-29), is a synthetic peptide analog of growth hormone-releasing hormone (GHRH)designed for laboratory research applications. This CJC 1295 peptide consists of 29 amino acidswith four targeted amino acid substitutionsat positions 2, 8, 15, and 27 designed to enhance resistance to enzymatic degradation while maintaining GHRH receptor affinity.

The compound has a molecular weight of approximately 3368.7 g/moland lacks the Drug Affinity Complex (DAC) conjugation, resulting in a shorter plasma half-life compared to DAC-bound variants.

Additionally, CJC-1295 without DAC has been studied for its ability to stimulate growth hormone (GH)releasein laboratory models and has applications in research exploring GH regulation and hypothalamic-pituitary axis signaling. This CJC 1295 10 mg vial is supplied as a stable lyophilized powder designed for reconstitution in controlled laboratory research settings.

CJC-1295 Without DAC Key Features and Benefits

CJC 1295 Peptide Formulation: Modified GRF (1-29) without Drug Affinity Complex for investigating growth hormone-releasing hormone receptor signaling in research models
Enhanced Enzymatic Stability: Four amino acid substitutions (positions 2, 8, 15, and 27) improve resistance to proteolytic degradation while preserving receptor-binding capacity
Shorter Plasma Half-Life: Approximately 30-minute half-life without DAC modification, allowing discrete GH elevation with rapid clearance
Pulsatile GH Release Profile: Designed for research investigating episodic growth hormone secretion patterns and time-dependent GH effects in laboratory models
Research-Grade Lyophilized Powder: Provided in sterile vials for subcutaneous administration in preclinical models and in vitro research protocols
Verified Composition: Supplied with analytical verification of identity and purity (≥98%) using HPLC and mass spectrometry
For Laboratory Research Only: CJC 1295 for research into acute growth hormone responses, hypothalamic-pituitary axis physiology, and metabolic signaling in controlled experimental systems. Intended exclusively for qualified researchers conducting in vitro and animal model studies

CJC-1295 Without DAC Mechanism & Research Applications

CJC-1295 Without DAC functions as a GHRH receptor agonist, binding to pituitary somatotrophs to stimulate growth hormone release. In laboratory research, this modified GRF peptide has been evaluated for its ability to promote acute GH elevation in cellular and animal models. Unlike the DAC-bound version, CJC-1295 without DAC enables investigation of short-duration GH signaling eventsand episodic release patterns.

Researchers have used this peptide to explore somatotroph receptor activation, intracellular signaling cascades, andacute growth hormone secretionin preclinical systems. The short half-life allows precise temporal control over GH elevation, making it suitable for investigations into the hypothalamic-pituitary axis, growth hormone receptor kinetics, and acute metabolic responses in laboratory models.

The combination of enhanced stability andshort plasma half-lifesupports research into how pulsatile GH stimulation affects cellular processes and endocrine signaling in controlled experimental conditions.

CJC-1295 Without DAC Dosing & Observed Effects in Research

In preclinical studies, CJC-1295 Without DAC is typically administered at 60–90 μg/kg per injectionin animal models. Single and multiple-dose protocols have been employed depending on experimental design and research objectives.

Furthermore, CJC-1295 Without DAC exhibits a mean plasma half-life of approximately 30 minutes, with detectable GH elevation typically observed for 1-2 hours post-injection. This short half-life distinguishes this formulation from the DAC-conjugated version (which has a half-life of 6-8 days), allowing researchers to investigate acute, time-limited GH responses.

The observed research effects also include:

In laboratory studies, single injections at research doses have demonstrated dose-dependent increases in basal growth hormone levels and corresponding elevations in insulin-like growth factor-1 (IGF-1).
In animal models of growth hormone deficiency, repeated dosing over multiple weeks has shown effects on body weight and lean mass parameters.
Additionally, CJC-1295 has been reported to enhance pituitary GH mRNA expression in research systems.

Notably, all reported observations are from preclinical laboratory studies. No clinical trial data specific to the CJC-1295 without DAC formulation is available. This product is designed exclusively for controlled research applications.

CJC-1295 Without DAC Storage, Safety & References

For long-term stability, store CJC-1295 Without DAC at -20°C or below in a tightly sealed, light-protected container. For short-term use (days to weeks), room temperature storage (15–25°C) is acceptable. Once reconstituted with bacteriostatic water at pH 5-6, maintain refrigeration at 2–8°C and use within 5-7 days. Avoid multiple freeze-thaw cycles after reconstitution to preserve peptide integrity.

Laboratory Safety: Follow standard laboratory safety protocols including appropriate personal protective equipment (PPE) and aseptic techniques when handling. Dispose of materials in accordance with institutional biosafety and chemical waste guidelines.
Regulatory Status: CJC-1295 is not approved by the FDA for clinical, compounding, or therapeutic use. It is available for laboratory research purposes only under regulatory frameworks applicable to research chemicals. Researchers should be aware that the FDA has raised safety concerns regarding injectable formulations of CJC-1295 peptides, including potential risks related to immunogenicity and aggregation when compounded.

This product is intended exclusively for qualified researchers conducting controlled preclinical studies.